Q-omics provides the consensus-scored TENT4B profile across patient tissues and cancer cell-line models. TENT4B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TENT4B is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TENT4B RNA expression shows 20,642 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TENT4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENT4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENT4B survival associations across molecular data types. TENT4B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENT4B RNA expression–survival associations across cancer types. High TENT4B expression shows unfavorable associations in LUSC, UVM, MESO and STAD, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TENT4B RNA expression.
This table summarizes TENT4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TENT4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENT4B shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, BRCA and CHOL. The HNSC box plot shows higher TENT4B RNA expression in tumor versus normal tissue (log2 FC = +0.671, t-test p < 0.001).
This table shows molecular features associated with TENT4B in patient tissues and cancer cell lines. In patient samples, TENT4B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TENT4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
